Is dose adjustment of eculizumab necessary in elderly patients?

Eculizumab is a monoclonal antibody that prevents the activation of terminal complement in some autoimmune conditions. ... Eculizumab has a long duration of ... Nov 14, 2024 ... The brand names of the eculizumab biosimilars are Bekemv and Epysqli. They are only available for the treatment of PNH and aHUS in countries which have ... Drug-induced liver injury (DILI), a rare, but potentially life-threatening drug reaction with elevated liver enzymes that may lead to liver failure or a need ... Feb 12, 2025 ... These studies suggest that eculizumab and ravulizumab are safe and effective treatments for people with AQP4-Ab+ NMOSD. Nov 25, 2008 ... Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008;142(2): ... eculizumab ... A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal ... Feb 15, 2025 ... You will need to receive a meningococcal vaccine at least 2 weeks before you begin your treatment with eculizumab to decrease the risk that you ... ALL prescribers and dispensing sites for ULTOMIRIS or SOLIRIS MUST be certified in the new, combined ULTOMIRIS and SOLIRIS REMS. You can certify here, or; You ... Paroxysmal Nocturnal Hemoglobinuria (PNH). SOLIRIS is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce ... Simple Search Results for: SolirisNew SearchNavigate to Advanced Search ; Biosimilar(s) · Epysqli · eculizumab-aagh ; Interchangeable(s) · Bkemv · eculizumab-aeeb.